###begin article-title 0
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer
###end article-title 0
###begin p 1
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 844 845 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1065 1068 1065 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1314 1319 1311 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 1472 1477 1466 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
The recent whole-genome scan for breast cancer has revealed the FGFR2 (fibroblast growth factor receptor 2) gene as a locus associated with a small, but highly significant, increase in the risk of developing breast cancer. Using fine-scale genetic mapping of the region, it has been possible to narrow the causative locus to a haplotype of eight strongly linked single nucleotide polymorphisms (SNPs) spanning a region of 7.5 kilobases (kb) in the second intron of the FGFR2 gene. Here we describe a functional analysis to define the causative SNP, and we propose a model for a disease mechanism. Using gene expression microarray data, we observed a trend of increased FGFR2 expression in the rare homozygotes. This trend was confirmed using real-time (RT) PCR, with the difference between the rare and the common homozygotes yielding a Wilcox p-value of 0.028. To elucidate which SNPs might be responsible for this difference, we examined protein-DNA interactions for the eight most strongly disease-associated SNPs in different breast cell lines. We identify two cis-regulatory SNPs that alter binding affinity for transcription factors Oct-1/Runx2 and C/EBPbeta, and we demonstrate that both sites are occupied in vivo. In transient transfection experiments, the two SNPs can synergize giving rise to increased FGFR2 expression. We propose a model in which the Oct-1/Runx2 and C/EBPbeta binding sites in the disease-associated allele are able to lead to an increase in FGFR2 gene expression, thereby increasing the propensity for tumour formation.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 494 499 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 720 725 720 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
Recently, a number of whole-genome association studies have identified genes that predispose individuals to common diseases such as cancer. The challenge now is to understand how the identified risk loci contribute to disease, since the majority of these loci are located within introns (which are discarded after transcription) and intergenic regions, and therefore do not change the coding region of nearby genes. This manuscript describes how two single-base pair changes in intron 2 of the FGFR2 (fibroblast growth factor receptor 2) gene, "the top hit" of the breast cancer susceptibility study, exert their function. We find that the changes alter the binding of two transcription factors and cause an increase in FGFR2 gene expression, thus providing a molecular explanation for the risk phenotype. This is the first functional study, to our knowledge, of the risk loci identified for breast cancer in a whole-genome scan and demonstrates that these studies can be used as valid starting points for studying the underlying biology of cancer.
###end p 4
###begin p 5
Recent whole-genome scans have identified novel risk genes for many common diseases, challenging researchers to determine how these genes contribute to disease. A new study provides molecular insights into a breast cancer risk factor.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b001">1</xref>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b002">2</xref>
###xml 728 733 728 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 738 743 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGF10</italic>
###xml 745 746 745 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b003">3</xref>
###xml 791 796 791 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b004">4</xref>
###xml 970 971 970 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b005">5</xref>
###xml 972 973 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b006">6</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b007">7</xref>
###xml 1077 1078 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b008">8</xref>
###xml 1289 1290 1289 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b009">9</xref>
###xml 473 478 <span type="species:ncbi:10090">Mouse</span>
###xml 612 617 <span type="species:ncbi:10090">mouse</span>
###xml 640 644 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 752 757 <span type="species:ncbi:9606">human</span>
FGFR2 (fibroblast growth factor receptor 2) plays a pivotal role both in mammary gland development and in cancer [1]. The FGFR2 gene encodes a transmembrane tyrosine kinase and can function as a mitogenic, motogenic, or angiogenic factor, depending on the cell type and/or the microenvironment. Mammary epithelial cells express FGFR2IIIb (including alternatively spliced exon 9), which binds FGF-7 and FGF-10, which are normally expressed by surrounding mesenchymal cells. Mouse models of mammary carcinogenesis have long established the FGF signalling pathway as a major contributor to tumorigenesis [2], and a mouse mammary tumour virus (MMTV) insertional mutagenesis screen for genes involved in breast cancer has identified FGFR2 and FGF10 [3]. In human breast cancer, the expression of FGFR2 has long been known to be elevated in estrogen receptor (ER)-positive tumours [4], which has been confirmed by data analysis performed with the ONCOMINE 3.0 array database [5,6]. Likewise both FGF-7 and FGF-10 have been found to be expressed in a proportion of breast cancers [7, 8]. Functional studies in cell lines have implicated FGFR2 as playing a role in tumourigenesis, with an alternative splicing in the C-terminal domain of FGFR2 giving rise to a more strongly transforming isoform [9]. However, as yet, nothing is known about the mechanism by which FGFR2 acts as a risk factor in predisposition to breast cancer.
###end p 7
###begin p 8
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
We examined the functional implication of genetic variation in the FGFR2 haplotype associated with susceptibility to breast cancer and we demonstrate increased gene expression for the risk allele.
###end p 8
###begin title 9
Results
###end title 9
###begin p 10
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b010">10</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b011">11</xref>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b010">10</xref>
###xml 305 313 305 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g001">Figure 1</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b012">12</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b013">13</xref>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 691 692 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b014">14</xref>
###xml 974 979 974 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 1054 1055 1054 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1066 1074 1066 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g002">Figure 2</xref>
###xml 1334 1339 1334 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 1667 1672 1667 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
Two independent studies have identified FGFR2 as risk factor in breast cancer [10,11]. We have shown that in Europeans, the minor disease-predisposing allele of FGFR2 is inherited as a haplotype of eight single nucleotide polymorphisms (SNPs) covering a region of 7.5 kb within intron 2 of the gene [10] (Figure 1), in a haplotype block with no linkage disequilibrium with the coding region of the gene. Microarray gene expression analysis on the Nottingham City Hospital cohort, using both the Agilent [12] and the Illumina [13] platforms, indicated that FGFR2 is expressed at higher levels by tumours that are homozygous for the minor alleles than by those with the common alleles (Wilcox p < 0.05). Analysed tumours were all diploid for this region based on array-comparative genome hybridization data [14]. This correlation was independent of either ER expression or p53 mutation status of the cells. Quantitative TaqMan PCR analysis confirmed a significant increase in FGFR2 expression in rare homozygotes, as compared to common homozygotes (Wilcox p = 0.028) (Figure 2). We also examined expression of the FGFR2 ligands FGF-7, FGF-10, and FGF-22, which are usually produced by the surrounding stroma, in 45 normal breast samples as well as the microarray data on tumours, but we found no correlation with genotype. Furthermore, FGFR2 displays a very complex splicing pattern with the most commonly expressed variants of the N terminus of the gene either including exons 1, 2, and 3 or including exons 1 and 2, but lacking exon 3. Again, no correlation was observed between genotype and the presence or absence of exon 3. Thus, the risk genotype correlates with FGFR2 expression itself, rather than affecting its function through receptor-ligand interactions.
###end p 10
###begin title 11
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
Diagram of the FGFR2 Gene
###end title 11
###begin p 12
Genetic linkage is taken from HapMap, and the positions of the eight candidate SNPs (red lines) within intron 2 are indicated. The two SNPs for which data are presented in this study are shown in green. Red circle: original tagging SNP rs2981582.
###end p 12
###begin title 13
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
Correlation of FGFR2 Expression in Breast Tumours with Genotype
###end title 13
###begin p 14
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
Quantitative RT-PCR was carried out using a probe targeting the 3' UTR of FGFR2.
###end p 14
###begin p 15
###xml 294 302 294 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g001">Figure 1</xref>
###xml 572 580 572 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
###xml 774 782 771 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
###xml 917 919 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b015">15</xref>
###xml 922 930 916 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
###xml 1249 1257 1240 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
###xml 1440 1445 1431 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 1620 1628 1611 1619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
###xml 1805 1813 1796 1804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
###xml 1844 1853 1835 1844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060108-sg001">Figure S1</xref>
This correlation suggests that the functional SNPs map to a regulatory region within the gene, possibly by altering one or more transcription factor binding sites. Interactions between proteins from nuclear extracts and DNA were examined for the eight most strongly disease-associated alleles (Figure 1). Two of these candidate functional SNPs showed distinct binding patterns in electrophoretic mobility shift assays (EMSA). The common allele of rs7895676 (FGFR2-33) formed strong protein-DNA complexes with nuclear extracts from the breast carcinoma cell lines HCC1954 (Figure 3A) and PMC42 and from HeLa cells (unpublished data), whereas no binding was detected on the minor allele. Competition studies and supershift experiments identify the bound protein as C/EBPbeta (Figure 3A). We note that the FGFR2-33 sequence has considerable homology to the C/EBPbeta binding site from the interleukin 6 (IL-6) promoter [15] (Figure 3C). The heterogeneity of the observed protein-DNA complexes is most likely due to the presence of multiple C/EBPbeta isoforms. For rs2981578 (FGFR2-13), both alleles give rise to a strong protein-DNA complex in HCC1954 cell extracts. However, a second more slowly migrating complex was only seen on the rarer genotype (Figure 3B). Interestingly, both alleles are able to compete for both bands, suggesting that the formation of the upper complex depends on the presence of the lower complex. Inspection of the FGFR2 DNA indicated the presence of a perfect octamer binding site immediately adjacent to the SNP, while the SNP itself lay within a sequence with homology to Runx binding sites (Figure 3C). Competition studies and incubation with specific antisera shows that both alleles bind Oct-1, while only the minor allele binds Oct-1 and Runx2 in HCC1954 nuclear extracts (Figure 3B), as well as in PMC42 cells (Figure S1).
###end p 15
###begin title 16
Protein-DNA Interactions at FGFR2-33 and FGFR2-13 In Vitro and In Vivo
###end title 16
###begin p 17
EMSAs on (A) FGFR2-33 and (B) FGFR-13 minor (m) and common (c) alleles, using 5 mug (FGFR2-33) and 2 mug (FGFR2-13) of HCC1954 nuclear extracts. Competitor oligonucleotides (minor, common, and ER as negative control) and antisera are indicated above each lane.
###end p 17
###begin p 18
###xml 99 101 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b015">15</xref>
###xml 167 169 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b018">18</xref>
(C) Alignment of the sequence around FGFR2-33 with binding site of C/EBPbeta in the IL-6 promoter [15] and of FGFR2-13 with the Oct/Runx site in the beta-casein gene [18]. The SNP is shown in red and the allele binding the transcription factor is shown.
###end p 18
###begin p 19
###xml 74 77 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 209 215 <span type="species:ncbi:9986">rabbit</span>
(D) ChIP assays for FGFR2-13 and FGFR2-33. Enrichment for the minor (HCC70-/-) and the common (T47D+/+) genotype is given relative to a negative control (TRXR2, located on 22q11.2) after normalisation against rabbit IgG.
###end p 19
###begin p 20
###xml 139 140 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b016">16</xref>
###xml 667 675 664 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
To establish whether or not these sites were occupied in vivo, we carried out chromatin immunoprecipitation (ChIP) experiments using the ER+ breast cancer cell lines HCC70 and T47D, which are homozygous for the minor and the common FGFR2 alleles, respectively. In addition, we confirmed that these cell lines were diploid for the FGFR2 locus and only expressed the epithelial-specific isoform FGFR2IIIb [16]. The ChIP analysis was carried out on homozygous cell lines, because the SNP overlapping the C/EBPbeta site lies in a repetitive region for which the different alleles could not be distinguished reliably by TaqMan PCR. A representative experiment is shown in Figure 3D. After Runx2-precipitation, the FGFR2-13 site is enriched 2-fold for the minor versus the common allele, confirming the EMSA results. Western blotting indicated that Runx2 is more abundant in T47D cells, thus confirming that differential ChIP in the two cell lines is due to the presence of the SNP. Oct-1 precipitation did not yield enrichment of FGFR2-13 for either allele. The Oct-1 epitope may either be sequestered within a higher-order complex or the antisera used do not work efficiently in a ChIP assay. On the FGFR2-33 site, we observed a 1.7-fold enrichment of C/EBPbeta binding on the common allele. In addition, we observe that C/EBPbeta can also bind to the minor allele, although less efficiently. Both cell lines contain comparable amounts of C/EBPbeta as judged by Western blotting (unpublished data). In conclusion, both the C/EBPbeta and the Runx2 binding sites are occupied in vivo.
###end p 20
###begin p 21
###xml 312 320 309 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g004">Figure 4</xref>
###xml 553 561 550 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g004">Figure 4</xref>
###xml 568 577 565 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060108-sg002">Figure S2</xref>
###xml 815 816 812 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1432 1433 1426 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1566 1574 1557 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g003">Figure 3</xref>
To test whether differential protein binding could alter the ability of the susceptibility alleles to activate transcription, we multimerised oligonucleotides overlapping both the Oct-1/Runx2 and the C/EBPbeta binding sites, cloned these in both orientations upstream of the luciferase reporter gene in pGL3Enh (Figure 4A), and assayed them in three breast cancer cell lines (PMC42, HCC70, and T47D). Transfections were carried out in triplicate and repeated at least twice for each cell line. A representative transfection into HCC70 cells is shown in Figure 4B (see Figure S2 for PMC42 and T47D). In all three cell lines tested, the minor allele at the Oct-1/Runx2 site stimulated transcription 2- to 5-fold over the common allele, independent of orientation, with the average being just above a 3-fold increase (p < 0.01). In contrast, the minor and common alleles of the multimerised C/EBPbeta binding site did not show a consistent pattern of activation relative to each other. It varied with the cell lines and the orientation in which constructs were tested. Nevertheless, relative to the parental vector, the common allele always showed transcriptional activation. Compared to the common allele, the minor allele was either not significantly different or gave rise to a smaller degree of activation. However, in the latter case, the rare allele still activated transcription significantly above the enhancer-only construct (p < 0.01). Presumably this reflects the fact that the minor allele of FGFR2-33 still binds C/EBPbeta above background levels in vivo (Figure 3D). By comparing the two different sites, we found that for Oct-1/Runx2 the minor allele was more active, while for C/EBPbeta, the common site yielded higher levels of transcription in the majority of experiments. Hence their effects were opposing. We therefore assayed a synthetic construct consisting of single sites for C/EBPbeta, Oct-1, and Runx2. In this arrangement, the effect of Oct-1/Runx2 clearly predominates, with the minor allele expressed at higher levels, reflecting the situation at the endogenous locus.
###end p 21
###begin title 22
Transcriptional Activation by the Minor and Common Alleles of Oct-1/Runx2 and C/EBPbeta Binding Sites of FGFR2
###end title 22
###begin p 23
(A) Diagram of the concatemerised binding sites cloned into pGL3Enh.
###end p 23
###begin p 24
###xml 350 351 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 380 381 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 93 96 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(B) Luciferase assays in HCC70 cells. Results are given as fold increase over pEnh activity. CMV-beta-gal served as transfection control. The binding sites are indicated beneath each data point, with [Oct/Runx] and [C-EBPbeta] being trimerized, while [C/O/R] contained only a single binding site for C/EBPbeta, Oct-1, and Runx2. The asterisk denotes p-values <0.05 in a Student's t-test comparing the common versus the minor allele of each site.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b017">17</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b018">18</xref>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b019">19</xref>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b020">20</xref>
###xml 696 701 696 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 919 924 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 1221 1223 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b021">21</xref>
###xml 1637 1645 1622 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060108-g004">Figure 4</xref>
###xml 1803 1805 1782 1784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b022">22</xref>
###xml 296 301 <span type="species:ncbi:10090">mouse</span>
###xml 1783 1788 <span type="species:ncbi:9606">human</span>
The data presented here lead us to conclude that the Oct-1/Runx2 binding site is the dominant determinant of differential expression between the common and minor haplotypes of FGFR2. Although Runx2 is a master regulator of osteoclast-specific transcription, Runx2 also plays an important role in mouse mammary gland-specific gene expression [17], where Runx2 activity is dependent on Oct-1 [18]. It is intriguing to note that in bone cells, overexpression of constitutively active FGFR2 leads to increased levels of Runx2 mRNA [19]. FGFR2 in turn is responsive to Runx2 in osteoclasts via the OSE2 (osteoclast specific element 2) in its promoter [20]. The description here of a Runx2 site in the FGFR2 gene that is occupied in breast cancer cells, suggests that in the presence of the minor genotype, a similar positive feedback loop could also be established in breast cells. The role of the C/EBPbeta binding site on FGFR2 expression has been harder to define. The common allele binds C/EBPbeta more tightly and activates transcription more strongly in most cases. Yet in a composite construct the activity of the Oct-1/Runx2 site dominates. This may be because C/EBPbeta can directly bind to and synergize with Runx2 [21]. Thus, on the minor genotype, Oct-1 and Runx2 are present and able to synergize with the C/EBPbeta bound (as suggested from the ChIP experiments), giving rise to higher levels of transcriptional activation. This is supported by the finding that a single copy of the C/EBPbeta/Oct-1/Runx2 site gives rise to higher levels of activation than a concatemerized Oct-1/Runx2 site with six potential interaction sites (Figure 4A). A potential role for C/EBPbeta in tumour etiology is supported by the observation that C/EBPbeta is highly overexpressed in malignant human breast cells [22]. In conclusion, our evidence supports Oct-1/Runx2 as the probable primary determinant of activity, with C/EBPbeta contributing to the risk haplotype.
###end p 26
###begin p 27
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b023">23</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b023">23</xref>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 537 538 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 604 605 604 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 607 608 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b008">8</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b024">24</xref>
The increased risk in breast cancer conferred by the FGFR2 allele is predominant for ER+ breast tumours, while there is no significant increase in risk for ER- tumours. Genome-wide analysis of ER binding sites has revealed three potential ER binding sites within the FGFR2 gene [23], and ER and Oct-1/Runx2 may cooperate to increase gene expression. This is consistent with findings that Oct and ER sites often cluster [23]. The risk conferred by the disease-associated genotype may also depend on the signalling potential of FGFR2 in ER+ cells. FGF-7 is over-expressed only in breast tumours that are ER+ [8]. Elevated levels of FGFR2 may then contribute to the establishment of an autocrine signalling loop, reducing the cell's propensity to undergo apoptosis [24]. Alternatively, paracrine signalling by mesenchymally or luminally derived FGF-7 or -10 on cells overexpressing FGFR2 may also drive cell proliferation.
###end p 27
###begin p 28
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
###xml 761 766 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
To our knowledge, this is the first functional study on the risk loci recently identified for breast cancer. Our study demonstrates that SNPs identified by whole-genome scans can be used a valid starting points for studying the underlying biology of cancer. SNPs identified in other whole-genome scans for the genetic basis of complex diseases also primarily map in intronic or intergenic regions. Our observation that an identified SNP regulates the expression of the risk allele is therefore likely to be a common theme. Breast cancer is one of the most common cancers in the developed world. The FGFR2 minor allele carries only a small increase in risk and acts as part of a spectrum of risk factors. However, it has a high minor allele frequency (0.4), and FGFR2 is therefore likely to contribute to the incidence of breast cancer in many individuals.
###end p 28
###begin title 29
Materials and Methods
###end title 29
###begin title 30
Genotyping.
###end title 30
###begin p 31
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b010">10</xref>
DNA from the 170 tumour samples was genotyped using a fluorescent 5' exonuclease assay (TaqMan) and the ABI PRISM 7900 Sequence Detection Sequence (PE Biosystems) in 384-well format. Duplicate samples were included to assess concordance and quality of genotyping. The genotyping assay was designed for rs2981582, which tags the whole haplotype block associated with the disease [10].
###end p 31
###begin title 32
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR2</italic>
Analysis of FGFR2 gene expression.
###end title 32
###begin p 33
Analysis was performed on total RNA from breast tumour cases. cDNA was prepared with the TaqMan Reverse Transcription Reagents kit (Applied Biosystems) using random hexamers, according to the manufacturer's instructions. Expression levels were determined using a TaqMan Gene Expression Assay (Hs00240796_m1, Applied Biosystems) and normalized to four different housekeeping genes.
###end p 33
###begin title 34
Statistical analysis.
###end title 34
###begin p 35
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
To assess whether there were significant statistical differences between the expression levels across the genotype groups we used a Wilcoxon test, fitted using the R statistical framework. Elsewhere, Student's t-tests were carried out using Microsoft Excel.
###end p 35
###begin title 36
Cell lines and cell culture.
###end title 36
###begin p 37
###xml 108 112 <span type="species:ncbi:9913">calf</span>
Breast cancer cell lines HCC1954, HCC70, T47D, and PMC42 were cultured in RPMI supplemented with 10% foetal calf serum and penicillin/streptomycin under standard conditions. These cell lines have been characterised extensively, and karyotypes are available at the Cancer Genomics Program of the University of Cambridge ().
###end p 37
###begin title 38
EMSAs.
###end title 38
###begin p 39
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b025">25</xref>
###xml 399 407 395 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060108-st001">Table S1</xref>
###xml 539 541 531 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
Small-scale nuclear extracts and bandshifts were carried out as previously described [25], except that Complete Protease Inhibitors (Roche) were used. In supershift experiments, polyclonal antisera against Oct-1 (sc-232x), Runx2 (sc-10758x), and C/EBPbeta (sc-150x) were obtained from Santa Cruz Biotechnology, Inc and up to 8 mul were added per reaction, unless otherwise stated. Oligonucleotides (Table S1) were annealed to complementary strands, and the resulting BamHI overhangs filled in with Klenow enzyme, using radiolabelled [alpha32P]dCTP (GE Healthcare, UK).
###end p 39
###begin title 40
ChIP.
###end title 40
###begin p 41
###xml 274 282 274 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060108-st001">Table S1</xref>
###xml 432 434 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060108-b023">23</xref>
Primers were designed using Primer Express (Applied Biosystems) and Lasergene (DNA Star) to amplify regions of up to 100 bp comprising the SNPs of interest, plus one negative control (region of the genome not suspected to bind any of the transcription factors of interest) (Table S1). PCR amplification was carried out with Power SYBR Green Mastermix (Applied Biosystems), using 2 mul of precipitated and purified DNA as described [23]. The antisera were as in the EMSAs, except for C/EBPbeta, which was a polyclonal serum from Abcam, UK.
###end p 41
###begin title 42
Plasmid construction and luciferase assays.
###end title 42
###begin p 43
###xml 127 135 127 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060108-st001">Table S1</xref>
###xml 324 327 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The pGL3-Enhancer vector (Promega) was linearized with BglII and re-circularised in the presence of annealed oligonucleotides (Table S1). All constructs were verified by sequencing. DNA was prepared using Qiagen kits and transfected into tumour cell lines cultured in 24-well plates. Per well, 500 ng of reporter and 100 ng CMV-beta-galactosidase plasmid were tranfected using 2 mul of Fugene 6 (Roche), harvested 36-48 h later and extracts prepared using 100 mul Promega lysis buffer. Luciferase and beta-galactosidase activity in 25 mul was measured using Promega reagents. Results are given as ratios of luciferase over beta-galactosidase activity.
###end p 43
###begin title 44
Supporting Information
###end title 44
###begin title 45
EMSA on the Common and Minor Allele of FGFR2-13 using PMC42 Nuclear Extracts
###end title 45
###begin p 46
5 mug of nuclear extract and 8 mul of alpha-Oct-1 (ab15112), alpha-Runx2 (ab11906), and alpha-C/EBPbeta (ab32358) from Abcam, UK, were included as shown above the lanes. ns, non-specific binding.
###end p 46
###begin p 47
(3.04 MB AI).
###end p 47
###begin p 48
Click here for additional data file.
###end p 48
###begin title 49
Transcriptional Activation by the Minor and Common Alleles of Oct-1/Runx2 and C/EBPbeta binding sites of FGFR2
###end title 49
###begin p 50
(A) Diagram of the concatemerised binding sites cloned into pEnh. These constructs were assayed in the cell lines.
###end p 50
###begin p 51
###xml 85 88 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(B) PMC42 and (C) T47D cells. Results are given as fold increase over pEnh activity. CMV-beta-galactosidase served as transfection control. The binding sites are indicated beneath each data point, with [Oct/Runx] and [C-EBP] being trimerized, while [C/O/R] contained only a single binding site for C/EBPbeta, Oct-1, and Runx2.
###end p 51
###begin p 52
(238 KB PPT)
###end p 52
###begin p 53
Click here for additional data file.
###end p 53
###begin title 54
Oligonucleotides Used in This Study.
###end title 54
###begin p 55
Sequences in brackets show the two alleles (common/minor) of SNPs.
###end p 55
###begin p 56
(50 KB DOC)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
We wish to thank D. Easton, A. Dunning, and P. Pharoah for helpful discussion throughout the project and J. Carroll and K. Green for help and advice with ChIP assays.
###end p 58
###begin title 59
Abbreviations
###end title 59
###begin p 60
chromatin immunoprecipitation
###end p 60
###begin p 61
electrophoretic mobility shift assay
###end p 61
###begin p 62
estrogen receptor
###end p 62
###begin p 63
fibroblast growth factor receptor 2
###end p 63
###begin p 64
single nucleotide polymorphism
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors
###end article-title 66
###begin article-title 67
Fibroblast growth factor signaling in tumorigenesis
###end article-title 67
###begin article-title 68
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer
###end article-title 68
###begin article-title 69
###xml 86 91 <span type="species:ncbi:9606">human</span>
Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues
###end article-title 69
###begin article-title 70
ONCOMINE: a cancer microarray database and integrated data-mining platform
###end article-title 70
###begin article-title 71
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles
###end article-title 71
###begin article-title 72
###xml 34 38 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas
###end article-title 72
###begin article-title 73
###xml 126 131 <span type="species:ncbi:9606">human</span>
Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer
###end article-title 73
###begin article-title 74
###xml 78 83 <span type="species:ncbi:9606">human</span>
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE
###end article-title 74
###begin article-title 75
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 75
###begin article-title 76
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
###end article-title 76
###begin article-title 77
A gene-expression signature to predict survival in breast cancer across independent data sets
###end article-title 77
###begin article-title 78
###xml 33 38 <span type="species:ncbi:9606">human</span>
MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype
###end article-title 78
###begin article-title 79
High-resolution array-CGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
###end article-title 79
###begin article-title 80
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family
###end article-title 80
###begin article-title 81
###xml 72 77 <span type="species:ncbi:9606">human</span>
Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer
###end article-title 81
###begin article-title 82
The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression
###end article-title 82
###begin article-title 83
Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein
###end article-title 83
###begin article-title 84
The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2
###end article-title 84
###begin article-title 85
A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome
###end article-title 85
###begin article-title 86
CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression
###end article-title 86
###begin article-title 87
###xml 79 84 <span type="species:ncbi:9606">human</span>
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data
###end article-title 87
###begin article-title 88
Genome-wide analysis of estrogen receptor binding sites
###end article-title 88
###begin article-title 89
###xml 61 66 <span type="species:ncbi:9606">human</span>
Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2
###end article-title 89
###begin article-title 90
Activation of the immunoglobulin kappa 3' enhancer in pre-B cells correlates with the suppression of a nuclear factor binding to a sequence flanking the active core
###end article-title 90
###begin p 91
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. KBM, A-TM, BAJP conceived and designed the experiments. KBM, A-TM, MO performed the experiments. AET analyzed the data. S-FC, CC contributed reagents/materials/analysis tools. KBM, A-TM wrote the paper.
###end p 91
###begin p 92
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. We acknowledge the support of The University of Cambridge, Cancer Research UK, Hutchison Whampoa Limited and the NIHR Cambridge Biomedical Research Centre. BAJP is the Li Ka Shing Professor of Oncology at the University of Cambridge.
###end p 92
###begin p 93
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 93

